Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia

<p><strong>PURPOSE:</strong> Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, approved for treatment of IDH1-mutant (mIDH1) acute myeloid leukemia (AML). Preclinical work suggested that addition of azacitidine to ivosidenib enhances mIDH1 inhi...

Full description

Bibliographic Details
Main Authors:	DiNardo, CD, Stein, AS, Stein, EM, Fathi, AT, Frankfurt, O, Schuh, AC, Döhner, H, Martinelli, G, Patel, PA, Raffoux, E, Tan, P, Zeidan, AM, de Botton, S, Kantarjian, HM, Stone, RM, Frattini, MG, Lersch, F, Gong, J, Gianolio, DA, Zhang, V, Franovic, A, Fan, B, Goldwasser, M, Daigle, S, Choe, S, Wu, B, Winkler, T, Vyas, P
Format:	Journal article
Language:	English
Published:	American Society of Clinical Oncology 2020

Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia

Similar Items